This supports the notion that unfavorable, high GATA2 levels in AML promoted by the CEBPA-TET2 axis are not limited to CEBPADM AML, but also include cases where CEBPA expression is high for other reasons. The gene discussed is CEBPA; the disease is acute myeloid leukemia.